Analysts Set MiMedx Group, Inc (NASDAQ:MDXG) PT at $9.60

MiMedx Group, Inc (NASDAQ:MDXG) has received a consensus rating of “Moderate Buy” from the six analysts that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $9.60.

Several equities research analysts recently issued reports on the company. Citizens Jmp began coverage on MiMedx Group in a research note on Monday, February 23rd. They set a “market outperform” rating and a $10.00 price objective for the company. Weiss Ratings restated a “hold (c)” rating on shares of MiMedx Group in a research note on Monday, December 29th. Citigroup assumed coverage on shares of MiMedx Group in a research note on Monday, February 23rd. They issued a “market outperform” rating on the stock. Wall Street Zen lowered shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. Finally, Cantor Fitzgerald lowered their price objective on shares of MiMedx Group from $12.00 to $8.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 17th.

MiMedx Group Trading Down 1.2%

Shares of MiMedx Group stock opened at $4.12 on Friday. MiMedx Group has a 12-month low of $4.08 and a 12-month high of $8.11. The company has a current ratio of 4.32, a quick ratio of 3.92 and a debt-to-equity ratio of 0.06. The company has a market cap of $612.11 million, a price-to-earnings ratio of 12.88 and a beta of 1.60. The company’s 50-day moving average price is $5.03 and its 200-day moving average price is $6.29.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings results on Wednesday, February 25th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.09 by $0.05. The firm had revenue of $118.10 million during the quarter, compared to the consensus estimate of $106.78 million. MiMedx Group had a net margin of 11.60% and a return on equity of 29.37%. On average, equities analysts expect that MiMedx Group will post 0.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MiMedx Group

Large investors have recently added to or reduced their stakes in the company. Trigran Investments Inc. lifted its stake in MiMedx Group by 10.4% during the second quarter. Trigran Investments Inc. now owns 8,390,458 shares of the company’s stock worth $51,266,000 after purchasing an additional 790,901 shares during the last quarter. Vanguard Group Inc. increased its position in shares of MiMedx Group by 5.6% during the 4th quarter. Vanguard Group Inc. now owns 7,184,262 shares of the company’s stock valued at $48,637,000 after purchasing an additional 382,623 shares during the last quarter. State Street Corp raised its holdings in shares of MiMedx Group by 6.1% during the 4th quarter. State Street Corp now owns 3,813,796 shares of the company’s stock valued at $25,819,000 after buying an additional 219,190 shares in the last quarter. First Light Asset Management LLC raised its holdings in shares of MiMedx Group by 89.5% during the 3rd quarter. First Light Asset Management LLC now owns 3,652,952 shares of the company’s stock valued at $25,498,000 after buying an additional 1,725,458 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in MiMedx Group by 4.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,479,369 shares of the company’s stock worth $16,786,000 after buying an additional 97,036 shares during the last quarter. Hedge funds and other institutional investors own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.